Machine Learning

Backed by Pfizer Ventures, Enodia Therapeutics' novel AI platform aims to stop diseases by degrading proteins at their source, a major shift in drug discovery.

The merger creates a data and AI powerhouse focused on the Snowflake ecosystem, aiming to help enterprises scale artificial intelligence responsibly.

Paris-based Enodia Therapeutics lands €20.7M to advance its AI platform that degrades disease-causing proteins at the point of synthesis, targeting new cures.

A new campaign says indecision is the biggest business risk. Aily Labs' AI platform promises to end analysis paralysis and force confident, fast action.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The AI-powered marketplace adds advanced materials, CMMC compliance, and new manufacturing controls to meet demands from critical, regulated industries.

With new AI agents and the integration of Paradox, Workday aims to slash hiring times and fix scheduling chaos for a struggling frontline workforce.

Zoom launches a new grant program celebrating solo entrepreneurs using AI, signaling a strategic bet on the rapidly growing 'business of one' economy.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

Targa Exploration grows its El Zanjon project by 66% in a key gold district, signaling a major push to uncover a new discovery in Santa Cruz.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new partnership brings revolutionary 3D genome mapping from the lab to the clinic, offering new hope for patients with hard-to-treat cancers.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.